Ahmed Abdalbagi – Drug Interactions Every Healthcare Professional Must Know
Ahmed Abdalbagi, Pharmacist at Pharma Trading Co.Ltd., posted on LinkedIn:
”CRITICAL ALERT: Drug Interactions Every Healthcare Professional Must Know
Patient safety hinges on our vigilance. As medication experts, pharmacists play a pivotal role in intercepting dangerous drug interactions that can lead to hospitalizations, permanent harm, or worse.
Here are clinically significant interactions, updated with current guidelines, that demand our immediate attention:
Sildenafil (and all PDE5 inhibitors) + Organic Nitrates (Nitroglycerin)
Risk: Profound, refractory hypotension. This is an absolute contraindication. Life-threatening.
Clopidogrel + Omeprazole/Esomeprazole
Risk: Significant reduction in Clopidogrel’s antiplatelet effect due to CYP2C19 inhibition. Increases risk of stent thrombosis and cardiovascular events. Use Pantoprazole or Rabeprazole if PPI is essential.
Warfarin + NSAIDs or Metronidazole
Risk: Potentiated anticoagulation and synergistic GI irritation. High risk of major bleeding. Monitor INR closely; recommend paracetamol for pain.
Potassium-Sparing Diuretics+ ACEi/ARB (Captopril, Lisinopril)
Risk: Severe hyperkalemia. Mandatory potassium monitoring is required, especially in patients with renal impairment or diabetes.
Gentamicin + Loop Diuretics (Furosemide)
Risk: Additive ototoxicity. Permanent hearing damage can occur. Closely monitor renal function and avoid concurrent use when possible.
SSRIs+ NSAIDs/Aspirin
Risk: Significantly increased risk of upper GI bleeding. The combination requires gastroprotection with a PPI.
Ondansetron + Tramadol
Risk: Ondansetron can blunt the analgesic effect of Tramadol by inhibiting its activation via CYP2D6. Consider alternative antiemetics like Metoclopramide.
QTc-Prolonging Agents: Fluoroquinolones (Levofloxacin) + Macrolides (Clarithromycin) + Antipsychotics
Risk: Additive QTc prolongation, potentially leading to Torsades de Pointes. A critical consideration in polypharmacy patients.
Statins (Simvastatin, Atorvastatin) + CYP3A4 Inhibitors (Clarithromycin, Fluconazole)
Risk: Dramatically increased statin levels, leading to rhabdomyolysis and acute kidney injury.
Digoxin + Amiodarone / Clarithromycin / Verapamil
Risk: These drugs increase Digoxin serum concentrations, leading to Digoxin toxicity (nausea, bradycardia, arrhythmias). Dose reduction and close monitoring are essential.
Why This Matters:
Polypharmacy is on the rise. In our collaborative practice, a single alert from a pharmacist can be the line of defense against a preventable adverse drug event (ADE). Medication safety is a non- negotiable team sport.
What is the most critical drug interaction you’ve intervened on recently? Share your experience to elevate our collective practice.”
Stay informed with Hemostasis Today.
-
Oct 5, 2025, 11:38Marc Vasse: Very Honored to Have Been Invited to Moderate the Session "Haemostasis and Oncology'' at 25th Moroccan Days of Clinical Biology
-
Oct 5, 2025, 08:32Maria Elisa Mancuso: During Day 2 of the Annual EHC Conference We Discussed Very Rare Bleeding Disorders!
-
Oct 5, 2025, 08:21Mattia Galli Gives a Talk on Pharma Pulse About "De-escalation" of Antiplatelet Therapy in ACS
-
Oct 5, 2025, 07:56Rucha Patil: I Had An Opportunity to Deliver a Lecture on A Topic Close to My Heart at EHA 2025
-
Oct 4, 2025, 12:39Ahmed Abdalbagi - Drug Interactions Every Healthcare Professional Must Know
-
Oct 5, 2025, 12:43Nita Radhakrishnan and Colleagues on Tertiary Prophylaxis with Extended Half-life Factor in LMIC Settings
-
Oct 5, 2025, 12:15Laura Avila and Colleagues on Childhood DVT: Upper Extremity (UE) Post-thrombotic Syndrome (PTS)
-
Oct 5, 2025, 11:54Laura Girardi on Anticoagulant Treatment for Isolated Distal DVT: Finally Our Official Paper Is Out!
-
Oct 5, 2025, 08:11Nathan Connell: A Groundbreaking Study Has Just Been Published in Blood, From Vincent Muczynski and Colleagues
-
Oct 4, 2025, 12:38Andaleb Kholmukhamedov: Anticoagulation Management: Current Landscape And Future Trends
-
Oct 3, 2025, 15:31Anirban Sen Gupta and Andrew Shoffstall Collaboration on Bioinspired Synthetic Platelet Systems for Brain Injury Treatment
-
Oct 3, 2025, 15:07Shai Shen-Orr: Excited to Share that The Human Immunome Project (HIP) Has Launched Its Scientific Partner Network
-
Oct 2, 2025, 04:59Caterina Casari - Prizes for Innovators 2025 Winner!
-
Oct 2, 2025, 04:572025 Innovators Award: Ile de France Région Recognizes 3 Researchers Who Have Committed Themselves to The Innovation
-
Oct 1, 2025, 15:59Anirban Sen Gupta: Thrilled to share a great collaboration story in Nature Portfolio
-
Oct 5, 2025, 12:29Miguel Crato: I Feel I Must Always Be Strong, But That Wears Me Down
-
Oct 5, 2025, 07:39Paige Bingham: ''Be data-driven'', "Don't jump to conclusions", "Be intentional''- Few Gems Shared During Impactful Close the Gap session at Transform AF
-
Oct 4, 2025, 10:21Maria Elisa Mancuso: Chance to Listen to Inspiring Experiences of People Who Live With Bleeding Disorders
-
Oct 4, 2025, 10:04Stéphanie Roullet Gave Talk on Platelet-Inspired Nanoparticles at SFTH 2025 Congress
-
Oct 4, 2025, 09:55NBDF: Proud to See Our Own Teri F Willey Representing the Foundation in the Funding Rare Disease Research Webinar